An interim analysis of phase I clinical trial of MCC-465, a doxorubicin (DXR) encapsulated in PEG-immunoliposome, in patients with metastatic stomach cancer

Advances in Experimental Medicine and Biology

Volumn 519, Issue , 2003, Pages 179-193

  Matsumura, Y ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 DEOXYDOXORUBICINOL; DOXORUBICIN; DOXORUBICIN DERIVATIVE; DOXORUBICINOL; IMMUNOLIPOSOME; MACROGOL; MCC 465; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; BACKACHE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG RESEARCH; FEMALE; FEVER; FLUSHING; FOLLOW UP; GASTROINTESTINAL DISEASE; HAIR LOSS; HUMAN; HYPERTENSION; LEUKOPENIA; MALAISE; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PERFORMANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR; SHIVERING; SIDE EFFECT; SKIN DISEASE; STOMACH CANCER; STOMATITIS; TACHYCARDIA; TASTE DISORDER; THROMBOCYTOPENIA; URTICARIA; VOMITING;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG COMPOUNDING; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYETHYLENE GLYCOLS; STOMACH NEOPLASMS;

EID: 0038294605     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (21)

1. Matsumura Y, Maeda H: A new concept for macro-molecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46: 6387-6392, 1986
2. Maeda H, Matsumura Y: Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 6: 193-210, 1989
3. Matusmura Y, Maruo K, Kimura M, et al: Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn J Cancer Res 82: 732-741, 1991
4. Maeda H, Sawa T, and Konno T: Mechanism of tumor-targeted delivery of macro molecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Controlled Release 74: 47-61, 2001
5. Maeda H.: The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Advan. Enzyme Regul. 41: 189-207, 2001
6. Allen TM, Hansen C, Martin F, et al: Liposome containing synthetic lipid derivertives of poly (ethyleneglycol) show prolonged circulation half-lives in vivo. Biochem Biophys Acta 1066: 29-36, 1991.
7. Klibanov AL, Maruyama K., Torchilin VP, et al: Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 268: 235-237, 1990
8. Gabizon A, Catane R, Uziely B, et al: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54: 987-992, 1994
9. Gabizon A, Chemla M, Tzemach D, et al: Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J Drug Target 3: 391-398, 1996
10. Unezaki S, Maruyama K, Ishida O, et al: Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipathic poly (ethylene glycol) Int J Pharm 126: 41-48, 1995
11. Hosokawa, S, Hirakawa, Y, Niki, H, et al: Establishment of a human monoclonal antibody (hu-McAb) GAH, exhibiting a specific reactivity to viable cancer cells from fresh tissues and evaluation of the use of the antibody GAH in targeting cancer therapy. Presented at 92nd Annual Meeting of the American Association for Cancer Research, New Orleans, LA, March 24- 28, 2001
12. Nagaike, K, Tagawa, T, Niki, H, et al: Anti-Tumor Activity of imunoliposomes conjugated with Human monoclonal antibody-GAH and modified with a branched-PEG derivative in gastric cancers. Presented at 92nd Annual Meeting of the American Association for Cancer Research, New Orleans, LA, March 24- 28, 2001
13. Simon R, Freidlin B, Rubinstein L, et al.: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89: 1138-1147, 1997
14. Bangham AD, Standish MM, Watkins JC: Diffusion on univalent inos across the lamellae of swollen phospholipids J Mol Biol 13: 238-252, 1965
15. Northfelt DW, Dezube BJ, Thommes JA, et al: Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy J Clin Oncol 15: 653-659, 1997
16. Harrison M, Tomlinson D, Stewart S, et al: Loposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma J Clin Oncol 13: 914-920, 1995
17. Northfelt DW, Dezube BJ, Thommes JA, et al: Pegylated-Liposomal Doxorubicin Versus Doxorubicin, Bleomycin, and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma: Results of a Randomized Phase III Clinical Trial J Clin Oncol 16: 2445-2451, 1998
18. Muggia FM, Hainsworth JD, Jeffers S, et al: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation J Clin Oncol 15: 987-993, 1997
19. Gordon AN, Fleagle JT, Guthrie D, et al: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19: 3312-3322, 2001
20. Goren D, Horowitz AT, Zalipsky S, et al: Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies BR J Cancer 74: 1749-1756, 1996
21. Maruyama K, Takahashi N, Tagawa T, et al. Immunoliposomes bearing poloethylenglycol-coupled Fab' fragment show prolonged circulation time and high ectravasation into targeted solid tumors in vivo. FEBS Lett 413: 177-180, 1997